- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07949799
A STUDY OF SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF FXS6837 CAPSULES IN PARTICIPANTS WITH HEPATIC IMPAIRMENT AND NORMAL HEPATIC FUNCTION (FXS6837-I-102)
AN OPEN-LABEL, PARALLEL-GROUP CLINICAL STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF FXS6837 CAPSULES FOLLOWING A SINGLE DOSE IN PARTICIPANTS WITH MILD AND MODERATE HEPATIC IMPAIRMENT AND PARTICIPANTS WITH NORMAL HEPATIC FUNCTION
This is a single-center, single-dose, parallel-group, open-label phase I clinical study to evaluate the safety, pharmacokinetics, and pharmacodynamics of FXS6837 between participants with mild and moderate hepatic impairment and participants with normal hepatic function
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Approximately 24 participants with hepatic impairment and participants with normal hepatic function are planned to be enrolled into this study. Participants will undergo screening examinations from D-28 to D-1. Eligible participants will be admitted to the clinical study site on D-1. During the trial, participants will undergo laboratory tests, 12-lead ECG, vital sign observation, AE collection, and PK, PD, and plasma protein binding (PPB) sample collection.
Studietype
Registrering (Antatt)
Fase
- Fase 1
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Male or female, aged 18-70 years (both inclusive), at screening;
-
Weight ≥ 50 kg and ≤ 120.0 kg for males, weight ≥ 45 kg and ≤ 120.0 kg for females, and body mass index (BMI) 18.0-35.0 kg/m2 (both inclusive), at screening;
-
Subject is eligible to enter the study if:
- matched control subject: physical examination, vital signs, laboratory tests (hematology, serum chemistry, urinalysis, coagulation function, etc.), 12-lead ECG, abdomen ultrasound, and chest X-ray judged by the investigator to be normal or abnormal without clinical significance;
- Subject with mild or moderate hepatic impairment:Chronic hepatic impairment caused by primary liver diseases: this condition is defined as patients with a prior diagnosis of hepatic impairment whose liver function is assessed by the investigator to have been stable for ≥ 3 months on the basis of clinical manifestations, with Child-Pugh Class A/mild (5-6 points) or Class B/moderate (7-9 points).
Exclusion Criteria:
-
Patients with serious diseases of cardiovascular, respiratory, digestive, endocrine, renal, hematological, or neurological/psychiatric systems within 1 year prior to screening;
-
Positive T-SPOT test results during the screening period, considered to indicate active tuberculosis based on the participant's clinical symptoms, chest X-ray, and laboratory tests;
-
History of meningococcal infection, or history of meningococcal infection in first-degree relatives; Or confirmed history of infection with encapsulated microorganisms within 6 months prior to screening, including but not limited to Streptococcus pneumoniae, Klebsiella pneumoniae, and Haemophilus influenzae;
-
History of known or suspected immunodeficiency, hereditary or acquired complement deficiency; Or current use of immunosuppressants;
-
Pregnant or lactating women or those with positive pregnancy test results;
-
Subjects with hepatic impairment will not be eligible to participate in the study if any of the following exclusion criteria also apply:
- Drug-induced liver injury;
- History of liver transplantation;
- Presence of serious ascites or pleural effusion requiring puncture drainage;
- Hepatorenal syndrome;
- Diseases affecting biliary excretion, such as biliary cirrhosis, biliary obstruction, and cholestatic liver disease, within 3 months prior to screening;
- Serious portal hypertension rendering the patient unsuitable for participating in the study as assessed by the investigator;
- History of portosystemic shunt surgery, including transjugular intrahepatic portosystemic shunt;
- Current liver failure or complicated with Grade 2-4 hepatic encephalopathy;
- Suspected or confirmed liver cancer;
- Cirrhosis with complications such as esophageal or gastric variceal bleeding, spontaneous peritonitis, etc., that the investigator considers unsuitable for participation in the study, within 3 months prior to screening;
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Mild hepatic impairment
Arm 1:mild hepatic impairment, FXS6837 125mg orally once. |
Mild hepatic impairment, FXS6837 125mg orally once. |
|
Eksperimentell: Moderate hepatic impairment
Arm 2: moderate hepatic impairment, FXS6837 125mg orally once. |
Mild hepatic impairment, FXS6837 125mg orally once. |
|
Eksperimentell: Normal hepatic function
Arm 3: normal hepatic function FXS6837 125mg orally once. |
Mild hepatic impairment, FXS6837 125mg orally once. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Primary Pharmacokinetics(PK) parameter of FXS6837 in plasma:Cmax
Tidsramme: Up to Day 14
|
Maximum observed concentration (Cmax) |
Up to Day 14
|
|
Primary PK parameter of FXS6837 in plasma: AUC0-t
Tidsramme: Up to Day 14
|
Area under the plasma concentration-time curve from time 0 to time t (AUC0-t) |
Up to Day 14
|
|
Primary PK parameter of FXS6837 in plasma: AUC0-∞
Tidsramme: Up to Day 14
|
area under the plasma concentration-time curve from time 0 to infinity (AUC0-∞) |
Up to Day 14
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Secondary PK parameter of FXS6837 in plasma: Tmax
Tidsramme: Up to Day 14
|
Time to reach maximum concentration(Tmax) |
Up to Day 14
|
|
Secondary PK parameter of FXS6837 in plasma: t1/2
Tidsramme: Up to Day 14
|
Half-life (t1/2) |
Up to Day 14
|
|
Secondary PK parameter of FXS6837 in plasma: CL/F
Tidsramme: Up to Day 14
|
Apparent total plasma clearance (CL/F) |
Up to Day 14
|
|
Secondary PK parameter of FXS6837 in plasma: Vz/F
Tidsramme: Up to Day 14
|
Apparent terminal volume of distribution (Vz/F) |
Up to Day 14
|
|
PK parameter of unbound FXS6837 in plasma: Cmax,u
Tidsramme: Up to Day 14
|
Maximum unbound concentration (Cmax, u) |
Up to Day 14
|
|
PK parameter of unbound FXS6837 in plasma: AUC0-t, u
Tidsramme: Up to Day 14
|
Area under the unbound plasma concentration-time curve from time 0 to time t (AUC0-t, u) |
Up to Day 14
|
|
PK parameter of unbound FXS6837 in plasma: AUC0-∞, u
Tidsramme: Up to Day 14
|
Area under the unbound plasma concentration-time curve from time 0 to infinity (AUC0-∞, u) |
Up to Day 14
|
|
Incidence and severity of AE and SAE
Tidsramme: Up to Day 14
|
Incidence and severity of adverse events (AEs)/serious adverse events (SAEs), including abnormalities in clinical symptoms and vital signs, physical examination, 12-lead electrocardiogram (ECG), and laboratory tests |
Up to Day 14
|
|
Pharmacodynamics indicator of FXS6837. Change from baseline in peripheral blood complement Alternative Pathway activity
Tidsramme: Up to Day 5
|
Complement alternative pathway (AP) activity in peripheral blood.Complement alternative pathway (AP) activity will be measured in peripheral blood. Absolute change and percentage change from baseline to Day 5 will be assessed. |
Up to Day 5
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- FXS6837-I-102
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .